Mechanisms of fluoroquinolone monoresistance in Mycobacterium tuberculosis

FEMS Microbiology Letters

Volumn 353, Issue 1, 2014, Pages 40-48

  Lu, Jie ^a,b   Liu, Min ^c   Wang, Yufeng ^a   Pang, Yu ^b   Zhao, Zhuo ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c Liaoning Provincial Center for Disease Control and Prevention   (China)

Author keywords

Fluoroquinolone; Resistance mechanism; Tuberculosis

Indexed keywords

ALANINE; ASPARTIC ACID; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ENZYME; ETHAMBUTOL; GYRASE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BINDING AFFINITY; CONTROLLED STUDY; EFFUSION; GENE SEQUENCE; GYRA GENE; GYRB GENE; LETTER; MINIMUM INHIBITORY CONCENTRATION; MUTATIONAL ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PSTB GENE; RECOMBINANT GENE; TRANSCRIPTION REGULATION; DRUG EFFECTS; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MUTATION;

ESCHERICHIA COLI; MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS;

EID: 84898057432     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1111/1574-6968.12401     Document Type: Letter

References (50)

1. Almeida Da Silva PE & Palomino JC (2011) Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother 66: 1417-1430.
2. Aubry A, Veziris N, Cambau E, Truffot-Pernot C, Jarlier V & Fisher LM (2006) Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother 50: 104-112.
3. Banerjee SK, Bhatt K, Rana S, Misra P & Chakraborti PK (1996) Involvement of an efflux system in mediating high level of fluoroquinolone resistance in Mycobacterium smegmatis. Biochem Biophys Res Commun 226: 362-368.
4. Banerjee SK, Misra P, Bhatt K, Mande SC & Chakraborti PK (1998) Identification of an ABC transporter gene that exhibits mRNA level overexpression in fluoroquinolone-resistant Mycobacterium smegmatis. FEBS Lett 425: 151-156.
5. Banerjee SK, Bhatt K, Misra P & Chakraborti PK (2000) Involvement of a natural transport system in the process of efflux-mediated drug resistance in Mycobacterium smegmatis. Mol Gen Genet 262: 949-956.
6. Baysarowich J, Koteva K, Hughes DW et al. (2008) Rifamycin antibiotic resistance by ADP-ribosylation: structure and diversity of Arr. P Natl Acad Sci USA 105: 4886-4891.
7. Bhatt K, Banerjee SK & Chakraborti PK (2000) Evidence that phosphate specific transporter is amplified in a fluoroquinolone resistant Mycobacterium smegmatis. Eur J Biochem 267: 4028-4032.
8. Braibant M, Gilot P & Content J (2000) The ATP binding cassette (ABC) transport systems of Mycobacterium tuberculosis. FEMS Microbiol Rev 24: 449-467.
9. Campbell PJ, Morlock GP, Sikes RD et al. (2011) Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 55: 2032-2041.
10. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh ML, Goble M & Iseman MD (2004) Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 169: 1103-1109.
11. Cheng AF, Yew WW, Chan EW, Chin ML, Hui MM & Chan RC (2004) Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 48: 596-601.
12. Cole ST, Brosch R, Parkhill J et al. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537-544.
13. Da Silva PE, Von Groll A, Martin A & Palomino JC (2011) Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 63: 1-9.
14. De Rossi E, Ainsa JA & Riccardi G (2006) Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol Rev 30: 36-52.
15. Devasia R, Blackman A, Eden S et al. (2012) High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility. J Clin Microbiol 50: 1390-1396.
16. Donald PR & Van Helden PD (2009) The global burden of tuberculosis-combating drug resistance in difficult times. N Engl J Med 360: 2393-2395.
17. Drlica K & Malik M (2003) Fluoroquinolones: action and resistance. Curr Top Med Chem 3: 249-282.
18. Espinal MA, Laszlo A, Simonsen L et al. (2001) Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 344: 1294-1303.
19. Franzblau SG, Witzig RS, McLaughlin JC et al. (1998) Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J Clin Microbiol 36: 362-366.
20. Gillespie SH & Kennedy N (1998) Fluoroquinolones: a new treatment for tuberculosis? Int J Tuberc Lung Dis 2: 265-271.
21. Ginsburg AS, Grosset JH & Bishai WR (2003) Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 3: 432-442.
22. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD & Murray MB (2010) Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 51: 6-14.
23. Kim DH, Kim HJ, Park SK et al. (2010) Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182: 113-119.
24. Kohanski MA, Dwyer DJ, Hayete B et al. (2007) A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130: 797-810.
25. Lienhardt C, Glaziou P, Uplekar M, Lonnroth K, Getahun H & Raviglione M (2012) Global tuberculosis control: lessons learnt and future prospects. Nat Rev Microbiol 10: 407-416.
26. Long Q, Li W, Du Q et al. (2012) gyrA/B fluoroquinolone resistance allele profiles amongst Mycobacterium tuberculosis isolates from mainland China. Int J Antimicrob Agents 39: 486-489.
27. Mariam DH, Mengistu Y, Hoffner SE & Andersson DI (2004) Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob Agents Chemother 48: 1289-1294.
28. Maruri F, Sterling TR, Kaiga AW et al. (2012) A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 67: 819-831.
29. Morens DM, Folkers GK & Fauci AS (2004) The challenge of emerging and re-emerging infectious diseases. Nature 430: 242-249.
30. Nachega JB & Chaisson RE (2003) Tuberculosis drug resistance: a global threat. Clin Infect Dis 36: S24-S30.
31. Pang Y, Zhou Y, Wang S et al. (2011a) A novel method based on high resolution melting (HRM) analysis for MIRU-VNTR genotyping of Mycobacterium tuberculosis. J Microbiol Methods 86: 291-297.
32. Pang Y, Zhou Y, Wang S et al. (2011b) Rapid molecular identification of mycobacterial species in positive culture isolates using the biochip test. Int J Tuberc Lung Dis 15: 1680-1685.
33. Pang Y, Song Y, Xia H, Zhou Y, Zhao B & Zhao Y (2012) Risk factors and clinical phenotypes of Beijing genotype strains in tuberculosis patients in China. BMC Infect Dis 12: 354.
34. Pang Y, Lu J, Wang Y, Song Y, Wang S & Zhao Y (2013) Study of the rifampin monoresistance mechanism in Mycobacterium tuberculosis. Antimicrob Agents Chemother 57: 893-900.
35. Pantel A, Petrella S, Veziris N et al. (2012) Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. Antimicrob Agents Chemother 56: 1990-1996.
36. Pasca MR, Guglierame P, Arcesi F, Bellinzoni M, De Rossi E & Riccardi G (2004) Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob Agents Chemother 48: 3175-3178.
37. Piton J, Petrella S, Delarue M, Andre-Leroux G, Jarlier V, Aubry A & Mayer C (2010) Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase. PLoS ONE 5: e12245.
38. Poole K (2005) Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56: 20-51.
39. Sarin J, Aggarwal S, Chaba R, Varshney GC & Chakraborti PK (2001) B-subunit of phosphate-specific transporter from Mycobacterium tuberculosis is a thermostable ATPase. J Biol Chem 276: 44590-44597.
40. Siddiqi N, Das R, Pathak N, Banerjee S, Ahmed N, Katoch VM & Hasnain SE (2004) Mycobacterium tuberculosis isolate with a distinct genomic identity overexpresses a tap-like efflux pump. Infection 32: 109-111.
41. Sullivan EA, Kreiswirth BN, Palumbo L, Kapur V, Musser JM, Ebrahimzadeh A & Frieden TR (1995) Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 345: 1148-1150.
42. Surcouf C, Heng S, Pierre-Audigier C et al. (2011) Molecular detection of fluoroquinolone-resistance in multi-drug resistant tuberculosis in Cambodia suggests low association with XDR phenotypes. BMC Infect Dis 11: 255.
43. Takiff HE, Salazar L, Guerrero C et al. (1994) Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 38: 773-780.
44. Towbin H, Staehelin T & Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. P Natl Acad Sci USA 76: 4350-4354.
45. Von Groll A, Martin A, Jureen P et al. (2009) Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother 53: 4498-4500.
46. Wade MM & Zhang Y (2004) Mechanisms of drug resistance in Mycobacterium tuberculosis. Front Biosci 9: 975-994.
47. Wang JY, Lee LN, Lai HC et al. (2007) Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 59: 860-865.
48. Xu P, Li X, Zhao M et al. (2009) Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China. Antimicrob Agents Chemother 53: 3170-3172.
49. Zhao YL, Xu SF, Wang L et al. (2012) National survey of drug-resistant tuberculosis in China. N Engl J Med 366: 2161-2170.
50. Zhu C, Zhang Y, Shen Y et al. (2012) Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China. Diagn Microbiol Infect Dis 73: 260-263.